KUALA LUMPUR, 16 NOVEMBER 2020 - Ho Wah Genting Berhad (“HWGB” or the “Company”) (Bursa Stock Code: 9601) today announced that its wholly owned subsidiary HWGB Biotech Sdn Bhd’s (HWGB Biotech) joint venture partner, US-based E-MO Biology Inc. (EBI), entered into a new Clinical Trial Agreement (“New CTA”) with Roderick A. Comunale II MD Inc for its appointment as the principal investigator and appointed America Diagnostics & GeneScan Diagnostics Inc as the laboratory to commence Phase IV clinical research study on the effectiveness of poliomyelitis virus vaccine (PVV) for prevention of COVID-19.
This New CTA is the latest inked deal following EBI obtaining a Clinical Trial Agreement approval from the U.S. Food and Drug Administration (US FDA) to commence its Phase IV clinical research study on the PVV vaccine.
In this Phase IV clinical trial, the objective is to collect additional information about the side effects or long term risks and potential benefits, on top of how well the vaccine works when used widely on several thousand people.
To recap, EBI on 18 September 2020 signed an agreement to engage the services of Roderick A. Comunale II MD Inc. and America Diagnostics & GeneScan Diagnostics Inc to conduct a clinical research study entitled “Inactivated Polio Vaccine in prevention of COVID-19 in high risk population in a Phase IV study".
The study is focused on the effects of Inactivate Polio Vaccine-IPV, conducted according to the United States Food and Drug Administration approved protocol and to be provided by EBI.
Currently for Stage 1 and Stage 2, there will be a total 300 volunteers to be enrolled for the clinical study in the United States of America.
HWGB Biotech’s General Manager, Medical & Pharmaceutical Research, Dr. Yaman Walid Kassab said, "This agreement with Roderick A. Comunale II MD Inc and America Diagnostics & GeneScan Diagnostics Inc represents continued momentum toward our goal of advancing the clinical research of the potential indication of PVV vaccine for the prevention of COVID-19. We look forward to learning more about the potential of PVV vaccine in this trial with patients living with COVID-19."
ABOUT HO WAH GENTING BERHAD
Ho Wah Genting Berhad (“HWGB” or the “Company”) is principally engaged in investment holdings and the provision of management services to its subsidiaries. The Company had on 30 June 2020 diversified its existing businesses to include healthcare related industry which mainly involved in health supplement, biotechnology and health technology. In addition, the Company and its subsidiaries (“HWGB Group” or the “Group”) are also engaging in the businesses of investment holdings; manufacturing of wires and cables and moulded power supply cord sets and cable assemblies for electrical and electronic devices and equipment; trading of wires and cables; and travel agent and tour related services.
For more information on about HWGB Biotech, follow us on https://hwgbbiotech.com, http://subscription.hwgbbiotech.com, Facebook, LinkedIn and Telegram to view the latest updates about our company ventures in the healthcare industry.
Dr.Yaman Walid Kassab is an assistant Professor of Clinical Pharmacy. He obtained his PhD in Clinical Pharmacy at University Science Malaysia (USM) in 2013. He possesses 7 years of experience in the academia, specifically in the pharmacotherapy field. He is actively involved in medical research and publication and has published more than 40SCOPUS/ISI indexed research papers and has supervised more than 50 research projects and 20 postgraduate research students. He is also serving as an editorial Board member of several reputed international journals like “Frontiers in Pharmacology”, “Archives of Pharmacy Practice (APP)” , “Journal of Medical and Pharmaceutical Innovation (JMPI)” , ”Annals of Cardiology and Cardiovascular Diseases” , “Updates in Public Health and Preventive Medicine” He has been a member of many international professional bodies such as International Association of Therapeutic Drug Monitoring & Clinical Toxicology in CANADA, Syndicate of Syrian Pharmacists, Malaysian Association of Education in Medicine & Health Sciences, Malaysian Pharmaceutical Society.
Dr. Roderick A. Comunale (“Dr. Roderick”) specialised in Nephrology and Internal Medicine, in National City, California. He is currently practices at Roderick A. Comunale II MD Inc and is affiliated with Paradise Valley. Dr. Roderick is currently conducting a multi-centre clinical study entitled “Inactivated Polio Vaccine (“IPV”) in prevention of COVID-19 in high risk population in a Phase IV study", to study the effects of Inactivate Polio Vaccine-IPV.
America Diagnostics & GeneScan Diagnostics Inc. is a California company that principally involved in research, development and production of the companion diagnostics systems and biomedical assay development services.